Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pfizer-BioNTech Omicron-adapted versus original COVID-19 vaccine in unvaccinated East African adults
PACTR202306533302513Phase 3Not yet recruiting
- Sponsor
- Oxford BioMedica
- Start
- Apr 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 3 trial of tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Oxford BioMedica. Primary endpoint: Neutralizing antibody GMT against Omicron BA.4/BA.5 at day 28. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202306533302513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202306533302513.